إعلان
إعلان

GSK

GSK logo

GSK plc - ADR

49.13
USD
برعاية
-0.16
-0.33%
٣١ ديسمبر, ١٢:٣٨ UTC -5
مفتوح

تقارير أرباح GSK

النسبة الإيجابية المفاجئة

GSK تفوق 32 من 39 آخر التقديرات.

82%

التقرير التالي

بيانات التقرير القادم
٠٤ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$8.70B
/
$0.23
التغير الضمني من Q3 25 (Revenue/ EPS)
+1.78%
/
-58.18%
التغير الضمني من Q4 24 (Revenue/ EPS)
+7.17%
/
--

GSK plc - ADR earnings per share and revenue

On ٢٩ أكتوبر ٢٠٢٥, GSK reported earnings of 0.55 USD per share (EPS) for Q3 25, beating the estimate of 0.48 USD, resulting in a 12.80% surprise. Revenue reached 8.55 مليار, compared to an expected 8.57 مليار, with a -0.28% difference. The market reacted with a +5.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 8.70 مليار USD, implying an decrease of -58.18% EPS, and increase of 1.78% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
logo
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, GSK plc - ADR reported EPS of $0.55, beating estimates by 12.8%, and revenue of $8.55B, -0.28% below expectations.
The stock price moved up 5.1%, changed from $43.70 before the earnings release to $45.93 the day after.
The next earning report is scheduled for ٠٤ فبراير ٢٠٢٦.
Based on 9 analysts, GSK plc - ADR is expected to report EPS of $0.23 and revenue of $8.70B for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان